- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06083142
Fecal Microbiota Transplant for Autobrewery Syndrome
The goal of this clinical trial is to study fecal microbiota transplantation(FMT) by oral capsule in people already diagnosed with auto-brewery syndrome (ABS, also known as gut fermentation syndrome). The main question it aims to answer: Is FMT safe and feasible in this syndrome?
Participants will
- have a "gut cleanout" with oral antibiotics and a colon cleanse, similar to that administered before colonoscopy
- receive five oral doses of fecal transplant capsules over a week
- be followed for six months for safety and research samples
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is a single arm, open label pilot safety and feasibility study. Subjects will provide medical information related to their diagnosis of ABS. All subjects will have a baseline assessment (medical history, exam, blood and stool samples ) at Massachusetts General Hospital in Boston. Those enrolled will receive a gut clean out procedure and 5 doses of FMT capsules in the 7 days after the clean out. Each individual ABS patient will receive capsules generated from a single donor, to minimize the risk of transmission of infectious agents. All subjects receive active treatment; there is no placebo.
The primary objective of this study is to evaluate the safety and feasibility of the proposed procedures (antibiotic pretreatment, "clean out" and microbial restoration via capsule FMT), thus the primary endpoints will be collection of data regarding any FMT-related adverse events. Feasibility will be defined as taking 3 doses of FMT capsules which we believe can fully reconstitute a healthy microbiome based upon our and others work.
Safety will be assessed daily for 7 days after FMT, and the intermitently over the 6 months after FMT, using standardized patient report scales and interviews as well as by clinical laboratories (at baseline and 2 weeks 2 months, and 6 months). Feasibility is defined as all subjects completing at least 3/5 planned doses of FMT capsules.
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Elizabeth Hohmann, MD
- Phone Number: 617-724-7532
- Email: ehohmann@partners.org
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18-70 with documented ABS symptoms for at least one year, including supervised ethanol testing or a positive glucose challenge test in a supervised setting.
- Active ABS including at least 3 flares by either serum or breath alcohol levels in the past year (blood or breath samples)
- Subject's microbiome produces alcohol ex vivo in bioreactor (Schnabl laboratory)
- Willing and able to travel to Boston for in person assessment (modest reimbursement available)
- Willing to stop antifungals, and any other complimentary therapies for ABS, if taking
- Medically able to withstand clean out. If participants are over 60, the subject must have previously tolerated a prior colonoscopic "prep" as part of prior routine care.
- Local physician contact available
Exclusion Criteria:
- Unwilling/unable to swallow large capsules (e.g.esophageal stricture or hiatal hernia)
- Delayed gastric emptying syndrome
- Known chronic aspiration, or chronic nausea/vomiting
- Pregnant (pregnancy testing will be performed in women of childbearing potential; women over 52 with no menses for 12 months will not require testing)
- Patients with an acute active illness or acute exacerbation of underlying comorbid condition.
- Patients on unstable, or increasing immunosuppressive agents including high dose corticosteroids(40 mg prednisone daily or more), calcineurin inhibitors, escalating immunosuppression for organ rejection, active chemotherapy with expected neutropenia, current or neutropenia (ANC <1000) within the last year.
- Patients with decompensated cirrhosis, advanced HIV/AIDS, recent bone marrow transplant, or other severe immunodeficiency.
- Severe food allergy or intolerance (donors are omnivores and do not maintain dietary restrictions)
- Cannot document at least 2 COVID vaccinations. Those refusing all COVID vaccination are not eligible for FMT.
- Ulcerative colitis or Crohn's disease (microbiome manipulation may precipitate a flare of these illnesses).
- Active HIV, hepatitis B or C infection (subjects with prior treated hepatitis C must have undetectable viral load; HIV positive subjects must be receiving anti-retroviral therapy with undetectable viral loads x 1 year minimum, Hepatitis B core antibody positive subjects are allowed if negative HepB surface antigen and antibody)
- Taking warfarin (known to be affected by dietary and microbiome changes). NOACs do not exclude.
- On suppressive antibacterial agents, or expected to receive prophylactic antibacterials within the year, for example a patient with a prosthetic heart valve who routinely receives dental prophylaxis, or patient with chronic UTIs anticipated to need treatment frequently
- Known biliary structural abnormalities.
- Allergy to erythromycin, neomycin, or rifaximin.
- Type I diabetes mellitus
- History of pancreatitis or biliary sepsis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active FMT
Active FMT (5 doses) over 7 days.
Each dose contains 15 capsules.
|
Fecal microbiota transplantation capsules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0
Time Frame: Over 6 months.
|
Safety outcomes of special interest include: Fever, diarrhea, nausea, vomiting, pain/bloating, bacteremia or transmission of GI infection |
Over 6 months.
|
Adequate dosing of FMT
Time Frame: 7 days
|
Adequate dosing is defined as subjects completed the gut cleanse and ingesting at least 3/5 planned doses of FMT capsules
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood Alcohol Level
Time Frame: Over 6 months
|
Plasma blood alcohol level
|
Over 6 months
|
Stool bioreactor ethanol production
Time Frame: Over 6 monthis
|
Presence or absence of elevated alcohol level when stool is cultured in a bioreactor
|
Over 6 monthis
|
weight
Time Frame: over 6 months
|
Subject weight in kg
|
over 6 months
|
Microbiome analysis of stool samples
Time Frame: over 6 months.
|
Comparison of stool microbiome to subject's baseline and donor
|
over 6 months.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Elizabeth Hohmann, MD, MGH
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023p000579
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Auto-Brewery Syndrome
-
University Hospital, LimogesCompleted
-
ALK Nordic A/S, Danmark FilialCompletedHandling of Auto-injectorsSweden
-
Centre Hospitalier Universitaire DijonCompletedQuality of Life | Systemic Auto-immune DiseasesFrance
-
Medical College of WisconsinCompletedCancer | Effects of Chemotherapy | Unspecified Complication of Bone Marrow Transplant | Auto Immune DiseaseUnited States
-
University of CambridgeUniversity of Oxford; Stanley Medical Research Institute; McPin FoundationCompletedSchizophrenia | Psychosis | Auto Immune DisordersUnited Kingdom
-
Hospices Civils de LyonUnknown
-
University Hospital, BrestCompleted
-
Erasmus Medical CenterNationaal Epilepsie FondsCompletedEpilepsy | Auto-immune EncephalitisNetherlands
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Centre Hospitalier Universitaire de NīmesCompleted
Clinical Trials on Fecal microbiota transplantation capsules
-
Alice Højer ChristensenCompleted
-
Xiangyu KongNot yet recruitingAdvanced Gastric CancerChina
-
Montefiore Medical CenterCompletedIrritable Bowel SyndromeUnited States
-
Madhusudan (Madhu) Grover, MBBSRecruiting
-
Medical University of GrazBristol-Myers SquibbTerminatedMalignant Melanoma Stage III | Malignant Melanoma Stage IV | Fecal Microbiota TransplantationAustria
-
Assistance Publique - Hôpitaux de ParisRecruitingEnterobacteriaceae Infections | Fecal Microbiota TransplantationFrance
-
Children's Mercy Hospital Kansas CityUniversity of Pittsburgh; Stanford UniversityCompletedUlcerative Colitis (UC) | Inflammatory Bowel Diseases (IBD) | Crohn's Disease (CD)United States
-
The Second Hospital of Nanjing Medical UniversitySIR RUN RUN hospital of Nanjing Medical UniversityNot yet recruitingAttention-deficit/Hyperactivity DisorderChina
-
The Second Hospital of Nanjing Medical UniversityNot yet recruiting
-
The Second Hospital of Nanjing Medical UniversitySIR RUN RUN hospital of Nanjing Medical UniversityRecruiting